Cytologics

Executive Summary

Cytologics is a San Diego-based biotechnology company founded in 2015 that specializes in providing high-quality, ethically-sourced human immune cell products for research applications. The company maintains a ready-to-ship inventory of fresh and cryopreserved peripheral blood mononuclear cells (PBMCs) and other cell types, and offers custom cell processing and isolation services. By addressing the challenge of procuring reliable human biological material, Cytologics supports drug discovery, diagnostic development, and cell therapy research. The company serves the cell therapy and biologics sectors, positioning itself as a key enabler for preclinical and translational studies. As a private company with no disclosed funding rounds, revenue, or valuation, Cytologics operates in the competitive immune cell supply market. Its business model relies on partnerships with research organizations and the ability to scale cell sourcing while maintaining ethical standards. The company's low profile and limited public information suggest it is early-stage or bootstrapped. Given the lack of disclosed catalysts such as new product launches, partnerships, or regulatory milestones, the near-term investment outlook is uncertain. The conviction score is conservative, reflecting the company's niche but essential role in the research supply chain, tempered by its private nature and absence of clear growth triggers.